Diabetic Under 70 (Diabetics Below 70) - Clinical Trial...

Diabetic Under 70 (Diabetics Below 70)

This study is currently recruiting participants.
Verified by AstraZeneca, August 2007

Sponsored by: AstraZeneca

Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00516204

Purpose
A screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus coronary heart disease) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <70mg/dl for such patients with very high risk) are screened. The doctors therapy decisions after the screening will be documented and 8-10 weeks later the lipid profile of each patient will be evaluated again. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Condition Intervention
Diabetes
Hyperlipidemia
Atherosclerosis
Drug: Any cholesterol-lowering drug

MedlinePlus related topics: Cholesterol Diabetes Heart Diseases

Drug Information available for: Cholest-5-en-3-ol (3beta)-

U.S. FDA Resources

Study Type: Observational
Study Design: Screening, Longitudinal, Defined Population, Prospective Study

Official Title: Diabetic Under 70 (Diabetics Below 70)

Further study details as provided by AstraZeneca:

Estimated Enrollment: 1400
Study Start Date: July 2007

Eligibility
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.) who already receive cholesterol-lowering therapy
Exclusion Criteria:

Diabetics w/o CVD; diabetics who do not receive cholesterol-lowering therapy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00516204

Contacts

Contact: AstraZeneca Austria Clinical, Study Information 43 1 71131 277 paul.grundtner@astrazeneca.com

Locations

Austria
Research Site

Recruiting
Vienna, Austria

Sponsors and Collaborators

AstraZeneca

Investigators

Study Chair: Michael Roden, MD Chairs of the Austrian Diabetes Society

More Information

Study ID Numbers: NIS-CAT-CRE-2007/3
First Received: August 14, 2007
Last Updated: September 27, 2007
ClinicalTrials.gov Identifier: NCT00516204
Health Authority: Not required for this study:

Keywords provided by AstraZeneca:
Hyperlipidemia
Diabetics
NIS
Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.)

Study placed in the following topic categories:
Atherosclerosis
Arterial Occlusive Diseases
Heart Diseases
Hyperlipidemias
Metabolic Diseases
Diabetes Mellitus
Vascular Diseases
Constriction, Pathologic
Arteriosclerosis
Coronary Disease
Carotid Stenosis
Metabolic disorder
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on November 26, 2008